The Magnificent Seven are struggling...

As you probably know, the stock market has become concentrated in a handful of mega-cap stocks. The "Magnificent Seven" – Microsoft (MSFT), Apple (AAPL), Amazon (AMZN), Alphabet (GOOGL), Nvidia (NVDA), Meta Platforms (META), and Tesla (TSLA) – account for roughly one-third of the S&P 500 Index.

With everyone talking about AI, it would seem like a no-brainer to throw your money into these tech leaders.

But, as we've written before, these companies no longer deliver the triple-digit gains that investors enjoyed a couple years ago. The Magnificent Seven are trailing the overall S&P 500 this year. And Meta and Tesla are both falling... They've dropped 7% and 15% this year, respectively.

Here's what's happening... The more "obvious" a bet is in the markets, the less likely you'll make money on it. Everyone else is already there. The opportunity is priced in.

For a richly valued stock to keep going up, it has to keep beating expectations. Anything less, and it can fall – or even crash. That means big or trendy names like the Mag Seven or SpaceX (SPCX) can be risky investments.

My friend Whitney Tilson sees an opportunity in a very different part of the market...

In 1999, at the height of the dot-com bubble, Whitney made a huge bet...

He largely turned his back on the tech boom and instead focused on quality. This choice made him a millionaire and helped him build an elite $200 million hedge-fund firm through two market crashes.

Now that the Magnificent Seven aren't leading like they used to, there's space for new, quality innovators most investors would overlook.

According to Whitney, a setup is reopening that will give people the same opportunity he exploited in 1999.

Bet big on quality... and make huge gains.

He's sharing all the details next Thursday morning and naming the obscure stock that needs to be at the top of your buy list right now.

Click here to learn more.

Now, let's get to this week's Q&A... And as always, keep sending your comments, questions, and topic suggestions to feedback@healthandwealthbulletin.com. My team and I read every e-mail.

The Safe Way to Fast

Q: With your article on the risks of eating less, does that also apply to fasting? I've read it's a good way to keep off weight, but can you do it safely? – A.D.

A: Thanks for your question, A.D. I've long been a fan of intermittent fasting. Fasting very well may be part of the recipe for longevity.

Intermittent fasting involves switching between fasting and eating on a set schedule. But unlike starvation or the undernourishment issues we discussed last week, fasting is a purposeful choice that you can break from at any time.

My favorite method is the 5:2 method. Each week, you spend two nonconsecutive days eating just 25% of your typical number of calories... So for example: let's say you generally eat around 2,000 calories a day. With the 5:2 method, you'd pick two days a week (say, Monday and Thursday) and designate them as your fasting days. Then, one of those days, you'd aim to only eat 500 calories (25% of 2,000).

One easy way to get through those fast days is by doing what I like to do: "dinner to dinner" fasting.

When I'm dinner-to-dinner fasting, I'll have dinner the night before my fast. And then on my fast day, I don't eat until dinner. I'll still drink water and herbal or green tea. I'm also doing less vigorous activity on those days. I generally spend my fast days reading, walking, and meditating quietly.

Remember, fasting doesn't mean you're going days without enough calories or nutrients to maintain your health. It's not a starvation diet and should never lead to undernourishment.

If you try fasting, you might try a mobile app like "Lose It!" The app can help you track your daily eating habits to ensure you're getting what you need. But if you notice that even on your normal days, you're not getting enough calories and nutrients, or you begin to have symptoms of undernourishment, stop fasting.

What We're Reading...

Here's to our health, wealth, and a great retirement,

Dr. David Eifrig and the Health & Wealth Bulletin Research Team
September 4, 2026

Recent Articles

View Full Archives
Subscribe to Health & Wealth Bulletin for FREE
Get the Health & Wealth Bulletin delivered straight to your inbox.
About Health & Wealth Bulletin

Here at Health & Wealth Bulletin, our manifesto is to provide a guide for living well – at a good price and on your own terms.

We've told folks the secret to life-changing income in retirement, the exit plan that every investor needs, and the key to beating the market. And our team has been on the leading edge of reporting new discoveries like immunotherapy, the dangers of BPA, the truth about cholesterol, and more.

You see, huge corporate interests and corrupt government institutions would rather people didn't know about many of these concepts... The more ignorant the people are, the better for the government and corporate interests. This keeps folks dependent... and the "nanny state" alive. That's why we spend our days uncovering the truth and sharing it with readers.

Health & Wealth Bulletin is your free guidebook to intriguing health and wealth ideas. It's all about living the best life possible.

About the Editor
Dr. David "Doc" Eifrig
Dr. David "Doc" Eifrig
Editor

Dr. David "Doc" Eifrig has one of the most remarkable resumes of anyone we know in the finance industry. After receiving his Bachelor of Arts degree from Carleton College in Minnesota, he went on to earn a Master of Business Administration degree

from Northwestern University's Kellogg School of Management. There, he graduated on the Dean's List with a double major in finance and international business.

Doc then went to work as an elite derivatives trader at the Goldman Sachs investment bank. He spent a decade on Wall Street with several major institutions, including Chase Manhattan Bank and Yamaichi Securities (then known as the "Goldman Sachs of Japan").

That's when Doc's career took an unconventional turn. Sick of the greed and hypocrisy on Wall Street, he quit his Senior Vice President position to become a doctor. He graduated from Columbia University's postbaccalaureate premedical program and eventually earned his Medical Doctor degree with clinical honors from the University of North Carolina at Chapel Hill. While in medical school, he was elected president of his class and admitted to the Order of the Golden Fleece – the highest honor awarded at the university.

Doc also completed a research fellowship in molecular genetics at Duke University and became a board-eligible eye surgeon. Along the way, he has been published in scientific journals and helped start a small biotechnology company, Mirus Bio, which was sold to Roche for $125 million in 2008.

However, frustrated by Big Medicine's many conflicts, Doc began to look for ways to talk directly with individuals. He wanted to use his background to show them how to take control of their health and wealth. In 2008, Doc joined Stansberry Research and launched his publication, Retirement Millionaire. He has gone on to launch Retirement Trader, which uses options to help people construct safe, reliable income streams. Doc's Income Intelligence seeks out income-producing investments to maximize returns. Prosperity Investor helps investors unlock massive potential gains in health care investing. Every Monday through Friday, Doc shares his views on the latest in the financial and health industries – and tips on how to improve your own life – in Health & Wealth Bulletin.

Doc has also authored five books with four-star ratings (or better) on Amazon. In his spare time, he has run three marathons and several triathlons. He owns and produces his own wine (Eifrig Cellars) in northern Sonoma County, California. Doc is also the CEO of MarketWise, Stansberry Research's parent company.

Back to Top